LPAR1 and bone neoplasm: Wu et al. observed that inhibitors of LPAR1, RhoA, ROCK and P2X3R mitigated bone cancer pain and significantly attenuated the spontaneous responses induced by the P2X3R agonist α, β-meATP [34].